FTC Wants To Extend Actavis To Authorized Generics Deals

Law360, New York (August 16, 2013, 7:05 PM ET) -- The Federal Trade Commission on Wednesday urged a New Jersey federal judge overseeing private antitrust litigation targeting an authorized generics deal between Wyeth LLC and Teva Pharmaceuticals USA Inc. to apply the U.S. Supreme Court's recent pay-for-delay ruling to the case.

The FTC sought permission to file an amicus curiae brief arguing that a promise by a branded drugmaker not to launch its own authorized generic version of a drug during a generics company's exclusivity period functioned the same way that straight payments to generic-drug makers...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required